Navigation Links
LifeQuest World Corporation Proud Contributor to Dietary Supplement Education Alliance (DSEA)
Date:9/7/2007

timulatory dietary supplement discovered to date with respect to macrophage activation," says Dr. David Pasco, Assistant Director at NCNPR. The results of this research were published in Planta Medica (Pugh et al, 2001 67(8): 737-742).

The statements in the press release that relate to the company's expectations with regard to the future impact on the company's results from new products or actions in development are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995. The statements in this document may also contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Since this information may contain statements that involve risk and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results.


'/>"/>
SOURCE LifeQuest World Corporation Inc.
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related medicine news :

1. Oracle Corp. to help build worlds first "Digital Hospital"
2. The World Bank funds private Hospital in India
3. Exclusive breast-feeding advised for six months in infants recommends World Health Organization
4. Half of worlds children are passive smokers - damning disclosure from WHO
5. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
6. World SARS-free within weeks
7. Flu-Drugs Are Causing Resistance Across The World
8. Televisions ruling babys world!
9. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
10. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
11. World Health Organisation Takes a Historic Decision and Approves Treaty to Discourage Smoking
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine News(10 mins):Health News:www.RightMedicare.com Launches to Offer Non-Biased Medicare Enrollment Assistance 2Health News:Mike Lucas of GE Healthcare Recognized as the Lifeline for Minority Businesses; Receives the MMBDC 2009 President's Award 2Health News:The Kenneth Rainin Foundation Awards $457,000 in Grants to Support Dance, Theater, Film and Early Literacy in the San Francisco Bay Area 2Health News:The Kenneth Rainin Foundation Awards $457,000 in Grants to Support Dance, Theater, Film and Early Literacy in the San Francisco Bay Area 3Health News:Webmedx Announces #1 Ranking in KLAS 2009 Transcription Services Report 2Health News:Webmedx Announces #1 Ranking in KLAS 2009 Transcription Services Report 3Health News:Astronaut Balancing Act: Training to Help Explorers Adapt to a Return to Gravity 2Health News:Astronaut Balancing Act: Training to Help Explorers Adapt to a Return to Gravity 3Health News:Astronaut Balancing Act: Training to Help Explorers Adapt to a Return to Gravity 4
Breaking Medicine Technology:FDA Launches Orphan Drug Workshop at KGI 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6Research Compares MENOPUR 28R 29 With rFSH in GnRH Antagonist IVF Cycles 5586 1Research Compares MENOPUR 28R 29 With rFSH in GnRH Antagonist IVF Cycles 5586 2Research Compares MENOPUR 28R 29 With rFSH in GnRH Antagonist IVF Cycles 5586 3Clues to Hypertension in Kids May Be Seen in Bones 59798 1Clues to Hypertension in Kids May Be Seen in Bones 59798 2Detailed Results from RV 144 HIV Vaccine Trial Published Today in The New England Journal of Medicine and Presented at the AIDS Vaccine 2009 Conferenc 59795 1Detailed Results from RV 144 HIV Vaccine Trial Published Today in The New England Journal of Medicine and Presented at the AIDS Vaccine 2009 Conferenc 59795 2Detailed Results from RV 144 HIV Vaccine Trial Published Today in The New England Journal of Medicine and Presented at the AIDS Vaccine 2009 Conferenc 59795 3
Other Medicine Technology:Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 2Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 3Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 4Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 5Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 6Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 7Exforge Helps Vast Majority of Patients Effectively Control Their,Blood Pressure After Failing on Other Medicines, According to New,Clinical Data 8Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 2Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 3Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 4Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 5Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 6